The Worldwide Glycated Albumin Assay Market is Projected to reach USD 384.5 Million by 2030, at a CAGR of 8.4%

Glycated Albumin Assay Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Glycated Albumin Assay Market size is expected to reach $384.5 million by 2030, rising at a market growth of 8.4% CAGR during the forecast period.

The Type 2 Diabetes segment is leading the Global Glycated Albumin Assay Market by Application in 2022; thereby, achieving a market value of $190.2 million by 2030. When the body's capacity to regulate and use sugar as fuel is weakened, type 2 diabetes is a condition that can result. Glucose is a substitute for similar sugar. Because of this chronic condition, too much sugar is constantly circulating through the blood. Excessive blood sugar levels can eventually lead to issues with the cardiovascular, immune, and nervous systems.

The Diagnostic Laboratory segment would witness a CAGR of 8.5% during (2023 - 2030). These laboratories use glycated albumin assays to identify or diagnose diabetes and identify the best therapies. These blood and urine samples are examined for diabetes-related physiological indicators. Hospitals provide faster test results and are more accessible than reference laboratories. This is anticipated to aid in the expansion of this end-user category.

The North America region dominated the Global Glycated Albumin Assay Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $148 .3 million by 2030. The Europe market is poised to grow at a CAGR of 7.9% during (2023 - 2030). Additionally, The Asia Pacific market would witness a CAGR of 9.2% during (2023 - 2030).

Full Report: https://www.kbvresearch.com/glycated-albumin-assay-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Asahi Kasei Pharma Corporation (Asahi Kasei Corporation), EKF Diagnostics Holdings plc, Weldon Biotech India Private Limited, Hzymes Biotechnology Co., Ltd., Beijing Strong Biotechnologies, Inc., Diazyme Laboratories, Inc. (General Atomics), Abbexa Limited, Biomatik Corporation, Abnova Corporation and Geno Technology, Inc.

Global Glycated Albumin Assay Market Segmentation

By Application

• Type 2 Diabetes
• Type 1 Diabetes
• Prediabetes

By End User

• Hospitals & Diabetic Care Center
• Diagnostic Laboratory
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• Asahi Kasei Pharma Corporation (Asahi Kasei Corporation)
• EKF Diagnostics Holdings plc
• Weldon Biotech India Private Limited
• Hzymes Biotechnology Co., Ltd.
• Beijing Strong Biotechnologies, Inc.
• Diazyme Laboratories, Inc. (General Atomics)
• Abbexa Limited
• Biomatik Corporation
• Abnova Corporation
• Geno Technology, Inc.

Unique Offerings from KBV Research

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

Related Reports:

North America Market 2023-2030

Europe Market 2023-2030

Asia Pacific Market 2023-2030

LAMEA Market 2023-2030